Mavacamten (CAMZYOS) is a drug used to treat symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM). Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by abnormal thickening of the heart muscle, which may lead to left ventricular outflow tract obstruction and restrict the heart's pumping function. The mechanism of action of mavacamten is to target cardiac myosin, reduce myocardial contractility, and alleviate the obstruction of the left ventricular outflow tract.

Is Mavacamten (CAMZYOS) expensive? How much does a box cost?

Mavacamten has been marketed in China, but it has not been included in medical insurance. According to market research, the price of mavacamten produced by Bristol-Myers Squibb in the United States varies depending on the dosage. The specification of 2.5mg*28 capsules is priced at approximately $22,680, and the specification of 5mg*28 capsules is priced at approximately $36,000.

The above prices are only for reference. The specific price may vary due to factors such as policy adjustments, regional differences, and market supply and demand. When purchasing, one should make a choice based on the doctor's advice and their own economic situation. Mavacamten is a prescription drug, and patients should strictly follow the doctor's prescription when using it, take the medicine on time and in the right amount, avoid changing the dosage without authorization, and also understand the precautions, usage and dosage, and drug interactions of the drug.

What are the drug interactions of Mavacamten (CAMZYOS)?

According to the drug instruction, the drug interactions of mavacamten mainly include the following points. Before taking the drug, patients should inform the doctor of the drugs they are currently using, and the doctor will evaluate the risk of drug interactions and formulate an appropriate medication plan.

Effects of other drugs on mavacamten

Mavacamten is mainly metabolized by CYP2C19 and also affected by CYP3A4 and CYP2C9. Concurrent use with inducers or inhibitors of CYP2C19 and CYP3A4 may change the blood concentration of mavacamten and affect its efficacy.

Effects of mavacamten on other drugs

Mavacamten can induce CYP3A4, CYP2C9, and CYP2C19. When used in combination with substrate drugs of these enzymes, it may lead to a decrease in the plasma concentration of these drugs, thereby affecting their efficacy.

Interactions with drugs that reduce cardiac contractility

Concurrent use of mavacamten with drugs that reduce cardiac contractility (such as dipyridamole, ranolazine, verapamil combined with beta-blockers, diltiazem combined with beta-blockers) may produce additive negative inotropic effects, increasing the risk of left ventricular systolic dysfunction and heart failure symptoms.